Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City
Authors Díaz de León-Castañeda C, Altagracia-Martínez M, Kravzov-Jinich J, Cárdenas-Elizalde MR, Moreno-Bonett C, Martínez-Núñez JM
Received 1 November 2011
Accepted for publication 29 November 2011
Published 7 March 2012 Volume 2012:4 Pages 57—65
Review by Single-blind
Peer reviewer comments 2
Christian Díaz de León-Castañeda, Marina Altagracia-Martínez, Jaime Kravzov-Jinich, Ma del Rosario Cárdenas-Elizalde, Consuelo Moreno-Bonett, Juan Manuel Martínez-Núñez
Department of Biological Systems and Health Care, Biological and Health Sciences Division, Universidad Autónoma Metropolitana-Xochimilco, Mexico DF, Mexico
Introduction: Worldwide, diabetes mellitus presents a high burden for individuals and society. In Latin America, many people with diabetes have limited access to health care, which means that indirect costs may exceed direct health care cost. Diabetes is Mexico's leading cause of death.
Purpose: To evaluate the cost-effectiveness ratios of the most used oral hypoglycemic agents (OHA) in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City.
Design: A cross-sectional and analytic study was conducted in Mexico City.
Methodology: Twenty-seven adult outpatients with type 2 diabetes who were treated either with metformin or glibenclamide were included. Acarbose was used as an alternative strategy. The study was carried out from the perspective of Mexican society. Direct medical and nonmedical costs as well as indirect costs were evaluated using a structured questionnaire. Efficacies of all drug treatments were evaluated retrospectively. A systematic search was conducted to select published randomized clinical trials based on predetermined inclusion criteria, and treatment success was defined as glycosylated hemoglobin factor ≤ 7%. Efficacy data of each drug and/or combination were analyzed using meta-analysis. The Monte Carlo Markov model was used. Quality-adjusted life-years (QALY) were used as the unit of effectiveness; incremental and sensitive analyses were performed and a 5% discount rate was calculated. A hypothetical cohort of 10,000 patients was modeled.
Results: The odds ratios of the success of each drug treatment were obtained from the meta-analyses, and were the following: 5.82 (glibenclamide), 3.86 (metformin), 3.5 (acarbose), and 6.76 (metformin–glibenclamide). The cost-effectiveness ratios found were US$272.63/QALY (glibenclamide), US$296.48/QALY (metformin), and US$409.86/QALY (acarbose). Sensitivity analysis did not show changes for the most cost-effective therapy when the effectiveness probabilities or treatment costs were modified.
Conclusion: Glibenclamide is the most cost-effective treatment for the present study outpatient population diagnosed with type 2 diabetes in the early stages.
Keywords: cost-effectiveness, hypoglycemic, outpatients, type 2 diabetes
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML]
Other article by this author:
Altagracia-Martinez M, Kravzov-Jinich J, Martínez-Núñez JM, Ríos-Castañeda C, López-Naranjo F
Published Date: 8 June 2012
Readers of this article also read:
Yanik ME, Erfan G, Albayrak Y, Aydin M, Kulac M, Kuloglu M
Published Date: 12 December 2014
Childs SR, Casely EM, Kuehler BM, Ward S, Halmshaw CL, Thomas SE, Goodall ID, Bantel C
Published Date: 2 December 2014
Social cognition and its relationship to functional outcomes in patients with sustained acquired brain injury
Ubukata S, Tanemura R, Yoshizumi M, Sugihara G, Murai T, Ueda K
Published Date: 3 November 2014
Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
Moretti DV, Binetti G, Zanetti O, Frisoni GB
Published Date: 5 June 2014
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S
Published Date: 16 May 2014
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM
Published Date: 21 February 2014
Sung M, Chin CH, Lim CG, Liew HSA, Lim CS, Kashala E, Weng SJ
Published Date: 20 February 2014
Katona CL, Katona CP
Published Date: 19 February 2014
Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
Butros L, Boayue K, Mathew P
Published Date: 12 May 2011
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
Published Date: 6 August 2010